Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Circulating PCSK9 has been associated with increased platelet reactivity and adverse outcomes in patients with atherosclerotic cardiovascular disease.
However, the relative effects of additional PCSK9 inhibitions on platelet reactivity in patients on DAPT and chronic statin therapy has not been evaluated.
To answer this gap in knowledge, we performed a collaborative individual patient data meta-analysis of randomized controlled trials finding that, although PCSK9 inhibitors significantly reduced circulating lipoproteins, such reduction did not translate into any significant change in platelet reactivity at 4 weeks.
These results suggest that the effects of PCSK9 inhibitors are mostly related to plaque stabilization rather than an off-target effect on platelets.”
Read the full article here.
Article: Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled Studies
Authors: Luis Ortega-Paz, Yasushi Ueki, Claudio Laudani, Sylvain Losdat, Francesco Franchi, Ryota Kakizaki, Fabiana Rollini, Jonas Häner, Lorenz Räber, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Apr 6, 2026, 05:48Isaac Okello: Turning Point from Reliance on Foreign Exports to Self – Reliance Through Local Production of Medical Supplies
-
Apr 6, 2026, 05:34Lena Volland: Scientific Exchange in Bleeding Disorders at the WFH 2026 World Congress
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines